Related Experiment Video

Updated: Sep 15, 2025

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders
05:58

Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

Published on: February 3, 2021

3.7K

Apolipoprotein A-I Infusions in Coronary Artery Disease: A Systematic Review

Rimsha Ahmad1, Syed Sadam Hussain1, Saifullah Khan2

  • 1From the Department of Internal Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY.

Cardiology in Review
|July 17, 2025
PubMed

Insights

Apolipoprotein A-1 (apoA-1) infusions show promise for treating coronary artery disease (CAD) by improving HDL function and cholesterol clearance. This approach targets HDL functionality, not just cholesterol levels, for cardiovascular event reduction.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Pharmacology

Background:

  • Coronary artery disease (CAD) remains a leading global cause of mortality.
  • High-density lipoprotein (HDL) cholesterol-raising therapies have not consistently reduced cardiovascular events.
  • Focus is shifting towards HDL functionality, specifically cholesterol efflux capacity (CEC).

Purpose of the Study:

  • To review the rationale for using apolipoprotein A-1 (apoA-1) infusions.
  • To summarize the clinical trial landscape for apoA-1 infusions in CAD.
  • To explore apoA-1 as a novel therapeutic target for CAD.

Main Methods:

  • Review of preclinical studies on apoA-1's antiatherogenic effects.
  • Analysis of early-phase human trials involving apoA-1 infusions.
  • Examination of apoA-1's role in reverse cholesterol transport and CEC.

Main Results:

  • ApoA-1 infusions demonstrated antiatherogenic effects in preclinical models.
  • Early human trials suggest apoA-1 infusions enhance CEC and cholesterol clearance.
  • ApoA-1 infusions may offer a new strategy beyond raising HDL-C levels.

Conclusions:

  • ApoA-1 infusions represent a promising therapeutic strategy for CAD.
  • Targeting HDL functionality via apoA-1 is a key area for cardiovascular research.
  • Further clinical trials are evaluating apoA-1 infusions for CAD prevention and treatment.

Keywords:
HDL-mimetic therapyapolipoprotein A-1cholesterol efflux capacitycoronary artery diseasehigh-density lipoprotein

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

11.5K
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.2K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
40
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
25
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
37
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
60
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
38
Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.4K